AmpliPhi Biosciences Corp., a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics, announced Steve R. Martin will be its new chief financial officer.
“Steve brings to AmpliPhi a wealth of management experience and a proven ability to grow businesses, nurture talent and raise and manage capital,” said M. Scott Salka, CEO of AmpliPhi. “We are thrilled to welcome Steve to the team.”
AmpliPhi’s interim CFO, David E. Bosher, will remain with AmpliPhi as a consultant.
Prior to this appointment, Martin served as CFO of Apricus Biosciences, a publicly traded pharmaceutical company, for three years. Before that, he was CFO and interim CEO of BakBone Software, leading the sale of the company to Quest Software. He also has experience as a senior consultant to the CEO and acting chief accounting officer for Leap Communications, a $2 billion telecommunications company.
Martin worked in biosciences as CFO of Strategene Corp., later sold to Agilent Technologies, and as controller for Gen-Probe, later acquired by Hologic.
